Methylation status of the Epstein-Barr virus major latent promoter C in latrogenic B cell lymphoproliferative disease: Application of PCR-based analysis

American Journal of Pathology

Volumn 155, Issue 2, 1999, Pages 619-625

  Qian, Tao ^a   Swinnen, Lode J ^b   Yang, Jie ^a   Srivastava, Gopesh ^c   Robertson, Keith D ^a,d   Ambinder, Richard F ^a,e  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS ANTIGEN; VIRUS DNA;

ANTIGEN EXPRESSION; ARTICLE; BURKITT LYMPHOMA; CLINICAL ARTICLE; DNA METHYLATION; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IATROGENIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; NASOPHARYNX CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; TRANSPLANTATION;

EID: 0344980092     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9440(10)65157-7     Document Type: Article

References (41)

1. Kieff E: Epstein-Barr virus and its replication. Fields Virology. Edited by Fields BN, Knipe DM, Howley PM. Philadelphia, Lippincott-Raven, 1996, pp 2343-2396
2. Rickinson AB, Kieff E: Epstein-Barr Virus: Fields Virology, Edited by Fields BN, Knipe DM, Howley PM. Philadelphia, Lippincott-Raven Publishers, 1996, pp 2397-2446
3. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB: Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 1992, 176: 157-168
4. Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ: Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 1992, 176:169-176
5. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, Rickinson AB: Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 1987, 6:2743-2751
6. Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, Powis S, Belich M, Croom-Carter D, Lee S, Burrows SR, Trowsdale J, Moss DJ, Rickiuson AB: Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol 1995, 25:1374-1384
7. Masucci MG, Zhang QJ, Gavioli R, De Campos-Lima PO, Murray RJ, Brooks J, Griffin H, Ploegh H, Rickinson AB: Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells. Int Immunol 1992, 4:1283-1292
8. Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson A, Kieff E, Cohen JI: Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989, 321:1080-1085
9. Oudejans JJ, Jiwa M, Vandenbrule AJC, Grasser FA, Horstman A, Vos W, Kluin PM, Vandervalk P, Walboomers JMM, Meijer CJLM: Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders. Am J Pathol 1995, 147:923-933
10. Chadburn A, Cesarman E, Knowles DM: Molecular pathology of posttransplantation lymphoproliferative disorders. Semin Diagn Pathol 1997, 14:15-26
11. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, Young JW, Kernan NA, O'Reilly RJ: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994, 33:1185-1191
12. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995, 345:9-13
13. Lucas KG, Small TN, Heller G, Dupont B, O'Reilly RJ: The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996, 87:2594-2603
14. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM: Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996, 2:551-555
15. Murray PG, Swinnen LJ, Constandinou CM, Pyle JM, Carr TJ, Hardwick JM, Ambinder RF: Bcl-2 but not the EBV-encoded bcl-2 homologue, BHRF-1, is commonly expressed in post-transplantation lymphoproliferative disorders. Blood 1996, 87:706-711
16. Delecluse HJ, Kremmer E, Rouault JP, Cour C, Bornkamm G, Berger F: The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders. Am J Pathol 1995, 146:1113-1120
17. Cen H, Williams PA, McWilliams HP, Breinig MC, Ho M, McKnight JL: Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. Blood 1993, 81:1393-1403
18. Gratama JW, Zutter MM, Minarovits J, Oosterveer MA, Thomas ED, Klein G, Ernberg I: Expression of Epstein-Barr virus-encoded growth-transformation- associated proteins in lymphoproliferations of bone-marrow transplant recipients. Int J Cancer 1991, 47:188-192
19. Thomas JA, Hotchin NA, Allday MJ, Amlot P, Rose M, Yacoub M, Crawford DH: Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation 1990, 49:944-953
20. Robertson KD, Hayward DJ, Ling PD, Samid D, Ambinder RF: Transcriptional activation of the EBV latency C promoter following 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial. Mol Cell Biol 1995, 15:6150-6159
21. Robertson KD, Ambinder RF: Mapping promoter regions that are hypersensitive to methylation-mediated inhibition of transcription: application of the methylation cassette assay to the Epstein-Barr virus major latency promoter. J Virol 1997, 71:6445-6454
22. Robertson KD, Manns A, Swinnen LJ, Zong JC, Gulley ML, Ambinder RF: CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma, and Hodgkin's disease. Blood 1996, 88:3129-3136
23. Robertson KD, Ambinder RF: Methylation of Epstein-Barr virus genome in normal lymphocytes. Blood 1997, 90:4480-4484
24. Minarovits J, Minarovits-Kormuta S, Ehlin-Henriksson B, Falk K, Klein G, Ernberg I: Host cell phenotype-dependent methylation patterns of Epstein-Barr virus DNA. J Gen Virol 1991, 72:1591-1599
25. Ernberg I, Falk K, Minarovits J, Busson P, Tursz T, Masucci MG, Klein G: The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J Gen Virol 1989, 70: 2989-3002
26. Minarovits J, Hu L-F, Imai S, Harabuchi Y, Kataura A, Minarovits-Kormuta S, Osato T, Klein G: Clonality, expression and methylation patterns of the Epstein-Barr virus genomes in lethal midline granulomas classified as peripheral angiocentric T cell lymphomas. J Gen Virol 1994, 75:77-84
27. Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF: Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood 1998, 91:1373-1381
28. Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF: The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive. J Virol 1998, 72:7075-7083
29. Chiang AKS, Tao Q, Srivastava G, Ho FCS. Nasal NK-, and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma, and Hodgkin's disease. Int J Cancer 1996, 68:285-290
30. Masucci MG, Contreras-Salazar B, Ragnar E, Falk K, Minarovits J, Ernberg I, Klein G: 5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6, and latent membrane protein in the Burkitt's lymphoma line Rael. J Virol 1989, 63:3135-3141
31. McDonald LE, Kay GF: Methylation analysis using bisulfite genomic sequencing: application to small numbers of intact cells. BioTechniques 1997, 22:272-274
32. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992, 89:1827-1831
33. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-9826
34. Perlmann C, Saemundsen AK, Klein G: A fraction of Epstein-Barr virus DNA is methylated in and around the EcoR1-J fragment. Virology 1982, 123:217-221
35. Niedobitek G, Agathanggelou A, Rowe M, Jones EL, Jones DB, Turyaguma, P, Oryema J, Wright DH, Young LS: Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood 1995, 86:659-665
36. Pallesen G, Sandvej K, Hamilton-Dutoit SJ, Rowe M, Young LS: Activation of Epstein-Barr virus replication in Hodgkin and Reed-Sternberg cells. Blood 1991, 78:1162-1165
37. Smith PR, Griffin BE: Transcription of the Epstein-Barr virus gene EBNA-1 from different promoters in nasopharyngeal carcinoma and B-lymphoblastoid cells. J Virol 1992, 66:706-714
38. Ling PD, Rawlins DR, Hayward SD: The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein. Proc Natl Acad Sci USA 1993, 90:9237-9241
39. Hsieh JJ, Hayward SD: Masking of the CBF1/RBPJ kappa transcriptional repression domain by Epstein-Barr virus EBNA2. Science 1995, 268:560-563
40. Fuentes-Panana EM, Ling PD: Characterization of the CBF2 binding site within the Epstein-Barr virus latency C promoter and its role in modulating EBNA2-mediated transactivation. J Virol 1998, 72:693-700
41. Cesarman E, Chadburn A, Liu YF, Migliazza A, Dalla-Favera R, Knowles DM: BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 1998, 92:2294-2302